Cathy E. Nolan

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 591 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Edward B. Garon et al. · Clinical Cancer Research · 2012 · 551 citations · Full text

Medicine, Oncology, Pharmacology +17

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Sven de Vos, L. J. Swinnen, Dee Dee Wang et al. · Annals of Oncology · 2018 · 72 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, Andrew W. Roberts, Mary Ann Anderson et al. · Blood · 2012 · 40 citations

Medicine, Oncology, Pharmacology +16

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

John F. Seymour, Matthew S. Davids, John M. Pagel et al. · Journal of Clinical Oncology · 2013 · 33 citations

Medicine, Oncology, Pharmacology +13